Comparing surgical treatment outcomes in patients with different levels of drug-resistant tuberculosis

Pulmonary tuberculosis surgical treatment in patients with multiple and extensive drug-resistant mycobacterial infection

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN71922508

Enrollment

1259

Registered

2019-07-02

Start date

2011-10-16

Completion date

Unknown

Last updated

2019-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary tuberculosis Infections and Infestations

Interventions

Patients with determined drug resistance were enrolled in study and divided into five groups depending on drug resistance: extensively drug-resistant (XDR), multiple drug-restistant (MDR), poly-drug-r

cases with remained cavern under thoracoplasty were also included, because tendency for cavity closureis usually observed in terms up to 6 months.) - Palliative

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Every patient with a diagnosis of drug-resistant M tuberculosis admitted in our clinic between 2011 and 2017 was included in this study.

Exclusion criteria

Exclusion criteria: Patients with unknown drug resistance admitted in our clinic between 2011 and 2017

Design outcomes

Primary

Measure	Time frame
1. Presence of cavities in pulmonary tissue (CV+/CV-) determined with CT scan/digital X-ray on discharge from the hospital 2. Presence of M tuberculosis assessed using AFB smear test of sputum (AFB+/AFB-) using sputum fluorescent microscopy and culture method on discharge from the hospital	—

Secondary

Measure	Time frame
1. Presence of cavities in pulmonary tissue (CV+/CV-) determined with CT scan/digital X-ray every year for 5 years (1st, 2nd, 3rd, 4th, 5th year) after discharge 2. Presence of M tuberculosis assessed using AFB smear test of sputum (AFB+/AFB-) using sputum fluorescent microscopy and culture method every year for 5 years (1st, 2nd, 3rd, 4th, 5th year) after discharge 3. TB relapse assessed by clinical follow-up up to 5 years (1st, 2nd, 3rd, 4th, 5th year) after discharge. 4. Degree of disability assessed by checking patients' documentation and anamnesis (patentient's account of medical history) during follow-up up to 5 years (1st, 2nd, 3rd, 4th, 5th year) after discharge. 5. Survival assessed by follow-up up to 5 years (1st, 2nd, 3rd, 4th, 5th year) after discharge.	—

Measure

Time frame

1. Presence of cavities in pulmonary tissue (CV+/CV-) determined with CT scan/digital X-ray every year for 5 years (1st, 2nd, 3rd, 4th, 5th year) after discharge 2. Presence of M tuberculosis assessed using AFB smear test of sputum (AFB+/AFB-) using sputum fluorescent microscopy and culture method every year for 5 years (1st, 2nd, 3rd, 4th, 5th year) after discharge 3. TB relapse assessed by clinical follow-up up to 5 years (1st, 2nd, 3rd, 4th, 5th year) after discharge. 4. Degree of disability assessed by checking patients' documentation and anamnesis (patentient's account of medical history) during follow-up up to 5 years (1st, 2nd, 3rd, 4th, 5th year) after discharge. 5. Survival assessed by follow-up up to 5 years (1st, 2nd, 3rd, 4th, 5th year) after discharge.

—

Countries

Russian Federation

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026